Stryker Co. (NYSE:SYK) Holdings Decreased by LGT Capital Partners LTD.

LGT Capital Partners LTD. lowered its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,133 shares of the medical technology company's stock after selling 69,557 shares during the quarter. Stryker comprises about 2.9% of LGT Capital Partners LTD.'s holdings, making the stock its 13th largest position. LGT Capital Partners LTD. owned 0.06% of Stryker worth $76,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the 4th quarter worth about $25,000. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new stake in shares of Stryker during the 4th quarter worth about $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker during the 4th quarter worth about $33,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Stryker during the 3rd quarter worth about $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Remove Ads

Stryker Stock Performance

Stryker stock traded down $1.77 during mid-day trading on Wednesday, reaching $363.52. The company's stock had a trading volume of 1,559,119 shares, compared to its average volume of 1,218,285. The firm has a market cap of $138.71 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 2.93 and a beta of 0.95. The business has a 50 day moving average price of $382.76 and a 200-day moving average price of $373.33. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm earned $3.46 earnings per share. Sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Citigroup reaffirmed a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Finally, Barclays increased their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.